載入中
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
前收盤價
US$4.94
−US$0.02 · -0.40%
盤中時間採用ET。市場資料可能有所延遲。
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
日內區間
目前US$4.94
52週區間
目前US$4.94
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
51
合理估值
情緒
41
多空交錯
風險
45
風險偏高
動能
75
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
日內區間
目前US$4.94
52週區間
目前US$4.94
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 582萬 USD | — | 350萬 USD | 141.4萬 USD | 300萬 USD |
| 銷貨成本 | 153.2萬 USD | 290.7萬 USD | 160.5萬 USD | 45萬 USD | — |
| 毛利 | 428.8萬 USD | −290.7萬 USD | 189.5萬 USD | 96.4萬 USD | 300萬 USD |
| 研究與開發 | 2681.2萬 USD | 3436萬 USD | 3109.1萬 USD | 2896.5萬 USD | 3872.6萬 USD |
| 銷售、一般及管理費用 | 6503.1萬 USD | 2985.1萬 USD | 1900.4萬 USD | 1725.6萬 USD | 2164.4萬 USD |
| 營業費用 | 9373.6萬 USD | 6130.4萬 USD | 4903萬 USD | 5187.9萬 USD | 9283.6萬 USD |
| 利息收入 | 555.6萬 USD | 424.6萬 USD | 211.7萬 USD | 43.1萬 USD | 4萬 USD |
| 利息支出 | 374萬 USD | 420.8萬 USD | 41.8萬 USD | 73.6萬 USD | 365.6萬 USD |
| 折舊和攤銷 | 356.3萬 USD | 290.7萬 USD | 319.8萬 USD | 457.7萬 USD | 446.4萬 USD |
| 營業利益 | −8944.8萬 USD | −6421.1萬 USD | −4713.5萬 USD | −5091.5萬 USD | −8983.6萬 USD |
| 淨利 | 7118.3萬 USD | −6373.4萬 USD | −5418.8萬 USD | −3969.6萬 USD | −8493.6萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$17.67
上漲空間 257.69%| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2000年3月31日 | US$0.593Irregular | — | — |
除息 2000年3月31日
US$0.593
Irregular
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI894.48萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM600.96萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF367.24萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO147.29萬0.01%180億 USD0.06%US$112.66+0.50%
Simplify Propel Opportunities ETFSURI136.51萬1.79%7606.44萬 USD2.82%US$17.06-0.14%
iShares Micro-Cap ETFIWC71.58萬0.05%13.17億 USD0.60%US$183+0.11%
iShares Core S&P Total U.S. Stock Market ETFITOT59.64萬0.00%980.88億 USD0.03%US$169.66+0.64%
WisdomTree U.S. SmallCap FundEES46.69萬0.07%6.84億 USD0.38%US$65.48+0.06%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSimplify Propel Opportunities ETFSURIiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTWisdomTree U.S. SmallCap FundEESAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
